Clinical Insight – Misuse of Common Prescription Medications

Prescribed medications, though generally safe when taken as directed, can pose risks if taken in higher than prescribed doses or combined with other substances. This edition of Clinical Insight will highlight a few prescription medications that have been known to be misused: gabapentin, bupropion, and quetiapine.

Gabapentin (Neurontin®)

    • Gabapentin is a commonly prescribed drug for neuropathic pain and seizures and is often prescribed for off-label indications such as insomnia, anxiety, bipolar disorder, and migraines. 
    • It has become a sought-after drug of misuse, due to its low cost, classification as a federally non-controlled substance and its use as an alternative to opioids for pain management.
    • While misuse of gabapentin alone is concerning, a larger issue is the use of gabapentin in conjunction with other medications.
      • The majority of gabapentin misuse is in combination with other substances.  The most common class of drugs used in combination with gabapentin is benzodiazepines.  Other drugs found to be commonly misused with gabapentin include alcohol and opioids, among others.
      • Studies have found that misuse of gabapentin with opioids has been associated with a fourfold increased risk of respiratory depression and that gabapentin doses exceeding 900mg have led to a 60% increase in the odds of opioid related death. Gabapentin misuse with opioids is often as an adjunct to potentiate the “opioid high”.
    • Reasons for gabapentin misuse are varied and include recreational use, to control mood or anxiety, to potentiate the effects of substance abuse treatment, such as buprenorphine or methadone therapy, to treat pain, to reduce cravings or manage withdrawal from other abused drugs, or as a substitute for other drugs.
    • Effects experienced from gabapentin misuse include euphoria, sedation or relaxation, improved sociability, dissociation, increased energy and focus, and improvement in sleep quality. These effects were not dependent on a specific dose.
    • The majority of reports of individuals misusing gabapentin had prescriptions for it and did reveal taking higher doses than prescribed.
    • Street names of gabapentin include “Gabbies” or “Johnnies”.

 

Bupropion (Wellbutrin®, Zyban®)

    • Bupropion is a commonly prescribed antidepressant medication and also used for smoking cessation.
    • It shares some pharmacological properties with amphetamine, and abusers report a similar high to cocaine use, but with a lesser intensity. Misuse generally occurs in adolescents and young adults.
    • Individuals report ingesting it orally in doses much higher than prescribed, inhaling crushed tablets, or dissolving the crushed powder to inject it intravenously. Crushing the tablets bypasses the extended-release quality of the drug which causes a sudden rush of the drug to the brain, resulting in its desired stimulant effects.
    • Signs of bupropion misuse include extreme energy, loss of appetite, euphoria, insomnia, increased sense of self-esteem or excessive excitement.
    • Because bupropion is a drug that can lower the seizure threshold, even at therapeutic doses, seizures are a hallmark symptom of acute overdose with the drug. The onset of seizures can be delayed up to 24 hours in patients who take extended-release preparations.
    • Other signs of toxicity include fast heart rate, vomiting, hallucinations, agitation, lethargy, and tremors.  Cardiac toxicity can also occur in overdose situations.
    • Street names of bupropion include “Wellies”, “Dubs”, or “Barnies”.

 

Quetiapine (Seroquel®)

    • Quetiapine is an antipsychotic drug used to treat bipolar disorder and schizophrenia. It is also frequently prescribed to treat anxiety, depression, substance abuse disorder and to manage withdrawal symptoms from misused substances.
    • Misuse of this drug is often for its sedative effects and individuals will self-medicate symptoms of anxiety and insomnia. Other reasons for misuse include to reduce the crash from stimulant drugs such as cocaine, to substitute for other drugs, or to aid in withdrawal symptoms.
    • Studies found that 75% of quetiapine-related ER visits involved other substances, most commonly other prescription drugs. Benzodiazepines were the prescription drug class most often involved in these visits. Alcohol also played a role, and illicit drugs (primarily cocaine, heroin, and marijuana) found in combination with quetiapine accounted for approximately a quarter of quetiapine-related ER visits.
    • Most common toxic effects from misuse of quetiapine include lethargy, fast heart rate, slurred speech, agitation, dizziness, and confusion.
    • Street names of quetiapine include “Susie-Q”, “baby heroin”, “Quell” and “Squirrel”.  When used in combination with other drugs, it is referred to as “Maq-ball” (quetiapine and marijuana), or “Q-ball” (quetiapine plus cocaine or heroin).

 

Of note, the majority of misuse with these medications generally occurs in patients with a history of substance misuse or dependence.  

References:

Alyssa M Peckham Maria J Ananickal David A Sclar. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Management and Healthcare Policy 2018:11 109–116

Smith R, Havens J, Walsh, S. Gabapentin misuse, abuse and diversion: A systematic review. Addiction. 2016 July; 111(7): 1160-1174.

Stall, N, Godwin Je, Juurlink D. Bupropion abuse and overdose. CMAJ, September 16, 2014, 186(13). 1015.

Oppek, K, Koller G, Zwergal A, Pogarell O. Intravenous Administration and Abuse of Bupropion: A Case Report and a Review of the Literature. CMAJ, September 16, 2014, 186(13). 290-293.

Hanley M, Kenna G. Quetiapine: Treatment for substance abuse and drug of abuse.  CMAJ, September 16, 2014, 186(13). 611-618.

Kim S, Lee G, Jung H, Chang J. Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior? Journal of Research in Pharmacy Practice. Jan-Mar 2017. 6(1). 12-15.

Mattson M, Albright V, Yoon J, Council C. Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN). Subst Abuse. 2015. 9: 39-46.

Klein L, Bangh S, Cole J. Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics. West J Emerg Med. 2017;18(2) 243-250.


Discover more from Dominion Diagnostics

Subscribe to get the latest posts sent to your email.

Scroll to Top

Discover more from Dominion Diagnostics

Subscribe now to keep reading and get access to the full archive.

Continue reading

Mark Peters, Chief Financial Officer of Dominion Diagnostics

Mark Peters

Chief Financial Officer

Mark Peters joined Dominion Diagnostics in 2021 and serves as the company’s Chief Financial Officer. Mr. Peters is responsible for Dominion’s Financial Planning & Analysis, Accounting, and Revenue Cycle Management functions. He has over 25 years of financial, operations, and strategic management experience in public, private equity, and venture capital backed healthcare companies.

His experience includes executive roles at Seikagaku Corporation (Tokyo Stock Exchange), IST (now part of Integra LifeSciences), Health Language (now part of Wolters Kluwer), and management positions with IBM and PricewaterhouseCoopers.  

Mr. Peters is a licensed CPA and graduated with an MBA in Finance from The University of Notre Dame and a BBA in Accounting from The University of Texas. In his personal time, he enjoys the outdoors, sports, reading, and spending time with his family.

Mark A. McSally, Esq.

Chief Operating Officer / General Counsel

Mark A. McSally, Esq. joined Dominion Diagnostics in 1999 as Outside General Counsel and moved internally in 2006 to assume the role of Corporate Counsel.  He currently serves as Dominion’s Chief Operating Officer and General Counsel.

Mr. McSally is responsible for all aspects of Dominion’s legal and regulatory needs, including government relations and corporate compliance.  As Chief Operating Officer, he is involved in all aspects of the operational management of Dominion Diagnostics, providing oversight to the Payer Relations, Clinical Services, Laboratory, Research and Development and Client Services teams. 

Mr. McSally is a seasoned attorney with deep roots in Rhode Island’s South County. Mr. McSally holds a Bachelor of Arts in History, with honors, from the College of the Holy Cross and a Juris Doctorate, with honors, from Suffolk University Law School.  He has and continues to serve on a number of community boards.

Luke Jessen

Vice President, Sales & Marketing

Luke Jessen joined Dominion Diagnostics in 2010 and currently serves as its Vice President of Sales & Marketing.  Luke has over twenty-three years of experience in healthcare, including fifteen years in diagnostics. 

Prior to joining Dominion Diagnostics, Luke spent eight years working in pharmaceuticals and two and a half years educating health care providers on appropriate opioid prescribing as President & Founder of Opioid Compliance Consulting.  After Opioid Compliance Consulting was acquired by Riverside Partners in 2010, Luke joined Dominion Diagnostics as Western Regional Sales Director. 

Luke has a consistent track record of building highly successful sales teams and driving clinically appropriate results. 

He holds a Bachelor of Arts in Political Science from The Colorado College in Colorado Springs, Colorado.  In his free time, Luke enjoys spending time with his family, surfing, mountain biking, fly fishing, hiking, snow/water skiing, and playing pickleball.  Luke also volunteers in his community at Cherry Hills Community Church, where he serves as a Ruling Elder. 

John Hearn

Vice President, Business Development & Payer Relations

John joined Dominion Diagnostics in 2018. In addition to business development responsibilities at Dominion Diagnostics, he manages the payer relations and inside sales teams. John has over 25 years of business development experience with 14 being in the laboratory space.

Before joining Dominion Diagnostics, John was the Chief Marketing Officer for Pathway Diagnostics. His responsibilities included, business development, managing outside sales, compliance, market and business strategy as well as lab operations. Prior to Pathway Diagnostics, he worked for Cordant Health Solutions, where he sold and managed a 5000 specimen a month book of business that grossed over $48 million in annual revenue as well as managed the Southeast sales team. In 2010, he was hired by Quest Diagnostics to be an account executive. His call points were all specialties including OBGYN and pain management.

Prior to working in the healthcare space, he had a sales role with Fidelity Information Services in their risk management and payment processing division. During his career and with two fortune 500 companies, he has won multiple president club awards.

John has a Bachelor of Business Administration degree from the University of Mississippi. John enjoys being outdoors, playing golf and tennis, watching his three kids play sports and traveling with his family.

Jeff Nally

Senior Vice President, RCM & Corporate Compliance Officer

Jeff joined Dominion Diagnostics in 2014 and currently serves as the SVP of Revenue Cycle Management and is also the company’s Corporate Compliance Officer. Jeff has spent his 25+ year career in finance and the past 20 years focused on healthcare revenue cycle management.

Prior to Dominion Diagnostics Jeff lead the shared services center as the Senior Finance Director for The Mentor Network a national network of local health and human services offering community-based services to adults and children with intellectual and development disabilities. Prior to The Mentor Network Jeff spent 9 years at Perkinelmer leaving as the Director of Insurance and Consumer Billing over seeing revenue cycle management in multiple diagnostic laboratories.

Jeff drives revenue cycle management excellence through streamlined operations and better workflow. Jeff can assess distressed situations, quickly managing necessary change while delivering and improving results and employee success.

In his personal time, he enjoys golf, local sports, and spending time with family and friends.  Jeff is certified in health care compliance (CHC) and has a bachelor’s degree from Curry College.

Denise Driscoll, SPHR, CCP

Vice President, Human Resources

Denise Driscoll is an experienced human resource leader across various industry sectors. Her prior experience includes working for national and global organizations.

Ms. Driscoll’s prior healthcare experience includes the creation of a HR shared services organization for a regional healthcare system.  She’s led programs in support of highly engaged employee populations.  She has significant organizational design, compensation, and benefit management experience as well as in-depth experience with mergers and acquisitions. Her employee relations record includes creating and implementing performance and development systems in support of high-performing companies.

At Dominion Diagnostics, Ms. Driscoll is responsible for organizational health and is the senior executive sponsor of the cross-functional Employee Success Team, which fosters employee engagement through communication, wellness initiatives, and programs that promote connection and a strong sense of community.

Denise has a B.A. in Psychology from Drew University, and an M.B.A. with a concentration in HR from San Francisco State University.  In her free time, she enjoys yoga, hiking, listening to live music, and kayaking. Denise is active with the Rhode Island Community Food Bank, where she is Head of the HR Committee and serves on the Board.

David J. Molusis

Vice President, Information Technology

David J. Molusis joined Dominion Diagnostics in 2015 as Vice President of Information Technology. Mr. Molusis has over 25 years of experience as an accomplished healthcare IT leader and administrator. 

Prior to Dominion Diagnostics, Mr. Molusis held the position of Vice President, Sales & Marketing at Nashville based, Common Cents Systems, a software development firm for reference laboratories. Prior to that as Vice President & CIO at Clinical Laboratory Partners, a member of Hartford Health Care Corporation’s integrated healthcare delivery system. Before his role at Clinical Laboratory Partners, Mr. Molusis held a variety of career evolving positions, including Chief Information Officer, at VNA Health Care, the largest home health care organization in Connecticut.  Earlier in his career, he held various roles in IT, project management, software development and optimization. 

Mr. Molusis is also a contributing author to the industry publications of Laboratory Economics in 2007, The Dark Report in 2011, and most recently, Advance for Administrators of the Laboratory in 2014. 

Mr. Molusis holds a Master’s degree in Information Management from Rensselaer Polytechnic Institute, a Bachelor’s degree in Business Administration from Western Connecticut State University and project management certification from Villanova University. In his personal time, he enjoys the beach, skiing, travel, and spending time with his family and friends between Connecticut, Southern Maine and Florida. 

Charlene Johnson, PhD

Senior Vice President, Laboratory Operations & Quality

Dr. Charlene Johnson first joined Dominion Diagnostics in 2003 as the Director of Molecular Testing.  In 2009, she became the Assistant Laboratory Director for Dominion’s Rhode Island and Vermont laboratories. Dr. Johnson assumed the role of Laboratory Director in 2011, followed by Vice President of Laboratory Operations and Laboratory Director in 2013, and was promoted to serve as the company’s Senior Vice President, Laboratory Operations & Quality in 2021.

Under Dr. Johnson’s exemplary leadership, Dominion’s laboratories have expanded tremendously in both capacity and testing capabilities.  She has driven significant achievements in laboratory operations, research and development, and strategic growth.  The company counts on Dr. Johnson’s expertise and guidance to uphold its reputation for sound science and laboratory integrity. 

Prior to joining Dominion, Dr. Johnson worked as a Senior Research Fellow at the University of Texas Health Science Center in Houston, Texas. 

Dr. Johnson holds a Bachelor of Science from the College of William and Mary and received her PhD from Virginia Commonwealth University/Medical College of Virginia.

Carin Johnson

Senior Vice President, Customer Operations

Carin joined the organization in 2015 and currently holds the position of Senior Vice President of Customer Operations. With a career spanning over 30 years in healthcare management, including 16 years of specialization in laboratory diagnostics, she brings invaluable expertise to the industry.

Before joining Dominion Diagnostics, Carin served as the Field Operations Director at Calloway Labs, where she oversaw and directed nationwide operations. In this role, she played a integral role in driving operational improvements, with a strong focus on enhancing the customer experience. This resulted in increased productivity and streamlined procedures, making a substantial impact during her tenure.

Carin holds a Bachelor of Science in Business Management from the University of Maryland. In her free time, she enjoys spending time with her family, as well as running, hiking, and traveling.

Robert M. Garvey, Jr.

Chief Executive Officer

Bob joined Dominion Diagnostics in 2011 and serves as its Chief Executive Officer. He has over 35 years of experience in healthcare, including over three decades of leadership in laboratory diagnostics and diagnostic imaging. 

Prior to Dominion Diagnostics, Bob ran the Northeast division of Laboratory Corporation of America as the Senior Vice President, which generated over $800M in annual revenue. He drove considerable organizational change to improve quality, service levels and foster growth.

Before his role at LabCorp, he spent 12 years at Quest Diagnostics where he held various Vice President and General Manager roles. Early in his career, he held roles in sales and sales management at GE Healthcare. Bob has a proven track record of growing healthcare businesses and developing high performing teams.

He holds a Bachelor of Science in Finance from the University of Massachusetts – Lowell. In his personal time, he enjoys tennis, golf, hockey, traveling, reading and spending time with his family.